Laddar...
Rituximab in Chronic Lymphocytic Leukemia
Rituximab (Rituxan(®); Biogen Idec, San Diego, CA, USA) is a human-mouse chimeric monoclonal antibody specific for CD20, a surface glycoprotein expressed on B lymphocytes. Administration of rituximab as a single agent to patients with chronic lymphocytic leukemia (CLL) has limited clinical activity,...
Sparad:
| I publikationen: | Adv Ther |
|---|---|
| Huvudupphovsmän: | , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
2011
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5734916/ https://ncbi.nlm.nih.gov/pubmed/21725721 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-011-0032-2 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|